Riskpilot← Back to searchSign inGet full accessElect Bioscience AB
ABActiveOrg 5592465271Vollmervägen 12Business and other management consultancy activities · NACE 7020Est. 20201 employees
Revenue 2025
SEK 267K
-48% vs 2024
EBITDA margin
-32.4%
-181% vs 2024
Equity ratio
79.3%
Financial strength
Net profit 2025
SEK -17K
-121% vs 2024
| Revenue | SEK 267K | -48% |
| EBITDA | SEK -86K | -181% |
| Net profit | SEK -17K | -121% |
| Total assets | SEK 702K | -18% |
| Equity | SEK 557K | -3% |
| Employees | 1 | — |
Legal name
Elect Bioscience AB
Org number
5592465271
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
5 mars 2020
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall tillhandahålla konsulttjänster inom försäljning, affärsutveckling och företagsledning inom området life science och bioteknologi, äga och förvalta fast och lös egendom, innefattande värdepapper, samt bedriva därmed förenlig verksamhet. Bolaget skall också bedriva inredningsdesign och - snickeri samt därmed förenlig verksamhet.
Address
Vollmervägen 12
Email
camilla.huse.bondesson@conlega.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 130 | 510 | 267 |
| Staff expenses | — | — | — | −397 | −223 |
| EBITDA | −12 | −9 | −38 | 107 | −86 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −12 | −9 | −38 | 107 | −86 |
| Net financials | — | −2 | 2 | 2 | 0 |
| Profit before tax | −1 | −10 | 4 | 109 | −16 |
| Tax | −0 | −0 | — | −29 | −1 |
| Net profit | −1 | −10 | 4 | 80 | −17 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 807 | 674 | 638 | 861 | 702 |
| Equity | 500 | 489 | 493 | 574 | 557 |
| Long-term debt | 5 | 5 | 5 | 5 | 5 |
| Short-term debt | 123 | 0 | — | 143 | 71 |
| Total debt | 128 | 5 | 5 | 148 | 76 |
EBITDA margin
-32.4%
This company
15.8%
Market median
-305% vs market
20212025
Equity ratio
79.3%
This company
38.2%
Market median
+108% vs market
20212025
Return on equity
-3.0%
This company
18.4%
Market median
-116% vs market
20212025
Net profit margin
-6.2%
This company
8.1%
Market median
-177% vs market
20212025
Asset turnover
0.38×
This company
1.12×
Market median
-66% vs market
20212025
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Elect Bioscience AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Gösta Bondesson | Deputy Board Member | 0 companies |
| Anne Camilla Huse Bondesson | Board of Directors | 0 companies |